NVCR
Medical Devices · Healthcare
CFO
Equibles does not estimate personal net worth.
Get an email with a short summary when NovoCure Ltd publishes a filing, an earnings call transcript or a press release.
Get NVCR alertsChristoph Brackmann is recorded as CFO at NovoCure Ltd (NVCR). The newest filing on record that lists Christoph Brackmann as CFO at NovoCure Ltd (NVCR) is dated April 20, 2026. NovoCure Ltd reported in an 8-K filed October 30, 2024 that Christoph Brackmann was appointed Chief Financial Officer of the Novocure Group, effective January 1, 2025. The proxy statement of NovoCure Ltd reports total compensation of $4,163,398 for Christoph Brackmann in fiscal 2025, including a base salary of $541,102. Christoph Brackmann has spoken on 8 earnings calls across 1 company, most recently for NovoCure Ltd on October 29, 2026. NovoCure Ltd is classified in the Medical Devices industry within the Healthcare sector. Other leadership on record at NovoCure Ltd includes Asaf Danziger (CEO and Board Member), David Hung (CEO and Board Member), Frank Leonard (CEO and Board Member) and 7 others.
“On October 30, 2024, the Company announced the appointment of Christoph Brackmann, age 51, as the Chief Financial Officer of the Novocure Group, effective January 1, 2025.”
“This was a very strong commercial quarter. We generated $193 million in net revenue, an increase of 16% year-over-year. This includes contributions of $8 million and $4 million from Option LUA and Option PAX, respectively.”
“We continued our strong start to the year in Q2. Net revenue in the second quarter was $184 million, an increase of 16% year-over-year.”
“We had a strong start to the year, continuing our momentum from 2025. Net revenue in the first quarter was $174 million, an increase of 12% year-over-year.”
“We closed 2025 with continued momentum delivering record net revenue for both the quarter and full year. Fourth quarter net revenue was $174 million and full year net revenue totaled $655 million, representing eight percent year-over-year growth for both periods.”
“We continued our positive momentum this quarter with net revenues of $167 million, an increase of 8% from the third quarter last year. This was primarily driven by year-over-year active patient growth of 5% in our GBM franchise, notably by strong performance in France, Germany, and Japan.”
Start not stated–present
Last confirmed April 20, 2026
NVCR
Medical Devices · Healthcare
CFO
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | NovoCure Ltd (NVCR) | Chief Financial Officer | $541,102 | $4,163,398 |